- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02522351
Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia
Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke)
Study Overview
Status
Detailed Description
This trial will be a double blind, randomized, crossover, controlled, and interventional trial. Each subject will test 6 study samples in a randomized order at 5 mL of volume first then at 10 mL (12 samples maximum). The trial will last a maximum of one hour (a single study visit).
The total sample size is 47 enrolled subjects, 33 subjects completed. Patients will be females and males aged between 18 and 85 years with mild proven dysphagia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mild dysphagia as defined by a score between 3 and 5 on the Dysphagia Outcome and Severity Scale
- Patients aged between 18 and 85 years
- Ischemic/hemorrhagic cerebral cause (stroke)
- Able to understand French (oral and written)
- Cognitive capacity enough to understand study procedures
- Having health insurance (which in France is " social security")
- Having signed the consent form.
Exclusion Criteria:
- Any swallowing trouble not resulting from the current stroke
- History of inhalation pneumopathy, i.e. any pulmonary inflammation linked to the path of a solid or liquid food in the respiratory system
- Any physician diagnosed psychiatric illness
- Patient with a digestive fistula
- Any physician diagnosed food allergy
- Any known allergy to barium or any compound of the contrast product
- Confirmed or suspected perforated and occlusive syndrome
- Pregnant or lactating women
- Major respiratory disease needing oxygen (chronic respiratory insufficiency)
- Subject who cannot be expected to comply with the study procedures, including consuming the test products.
- Currently participating or having participated in another clinical trial during the month preceding the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Thicken Up Clear concentration 1
Thicken Up Clear at concentration 1
|
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
|
|
Active Comparator: Thicken Up Clear concentration 2
Thicken Up Clear at concentration 2
|
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
|
|
Active Comparator: Thicken Up Clear concentration 3
Thicken Up Clear at concentration 3
|
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
|
|
Experimental: Cereal extract concentration 1
Cereal extract at concentration 1
|
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
|
|
Experimental: Cereal extract concentration 2
Cereal extract at concentration 2
|
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
|
|
Experimental: Cereal extract concentration 3
Cereal extract at concentration 3
|
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification of any systematic effect of cohesiveness on the efficacy of swallowing in dysphagic patients according to Rosenbek's Penetration-Aspiration Score (PAS) using videofluoroscopy
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
The PAS score across each bolus (5 mL and 10 mL)
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Swallowing safety- prevalence of penetration
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
The prevalence of penetration in the population according to Rosenbek's PAS (score of 2-5) assessed using videofluoroscopy
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing safety- prevalence of aspiration
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
The prevalence of aspiration in the population according to Rosenbek's PAS (score of 6-8) assessed using videofluoroscopy
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function- Amount/volume of oral and pharyngeal residues
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
The amount/volume of oral and pharyngeal residues assessed using videofluoroscopy
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function- Prevalence of subjects with oral and pharyngeal residues
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
The prevalence of subjects of oral and pharyngeal residues assessed using videofluoroscopy
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function- Oral transit time (OTT, time between tongue tip elevation and arrival of the bolus at the ramus of the mandible)
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
Oral transit time (OTT, time between tongue tip elevation and arrival of the bolus at the ramus of the mandible)
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function- Swallow response time (SRT, time between arrival of the bolus at the ramus of the mandible and pharyngeal phases of swallowing)
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
Swallow response time (SRT, time between arrival of the bolus at the ramus of the mandible and pharyngeal phases of swallowing)
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function- Pharyngeal transit time (PTT, time between arrival of the bolus at the ramus of the mandible and the tail of the bolus passing through the upper esophageal sphincter)
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
Pharyngeal transit time (PTT, time between arrival of the bolus at the ramus of the mandible and the tail of the bolus passing through the upper esophageal sphincter)
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function- Time to upper esophageal sphincter opening (UESO, time between tongue tip elevation and opening of the upper esophageal sphincter)
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
Time to upper esophageal sphincter opening (UESO, time between tongue tip elevation and opening of the upper esophageal sphincter)
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function-Time to laryngeal vestibule opening (LVO, time between tongue tip elevation and pharyngeal phases of swallowing)
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
Time to laryngeal vestibule opening (LVO, time between tongue tip elevation and pharyngeal phases of swallowing)
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Swallowing function- Time to laryngeal vestibule closure (LVC, time between tongue tip elevation and maximal laryngeal closure)
Time Frame: During the ingestion (videofluoroscopy), maximum during one hour.
|
Time to laryngeal vestibule closure (LVC, time between tongue tip elevation and maximal laryngeal closure)
|
During the ingestion (videofluoroscopy), maximum during one hour.
|
|
Subjective perception of ease of swallowing and oropharyngeal sensation.
Time Frame: Right after ingredient ingestion, maximum during one hour.
|
This will be assessed from a questionnaire.
|
Right after ingredient ingestion, maximum during one hour.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13.21. NRC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
Clinical Trials on Cereal extract concentration 1
-
Pennington Biomedical Research CenterPepsiCo Global R&D; Quaker Oats CompanyCompletedFood Intake | SatietyUnited States
-
Frank GreenwayPepsiCo Global R&D; Quaker Oats CompanyCompletedFood Intake | SatietyUnited States
-
Harokopio UniversityNational and Kapodistrian University of AthensCompleted
-
Lund UniversityVinnova; Öste Venture ABCompleted
-
University of BathLucozade Ribena SuntoryCompleted
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
ALK-Abelló A/STerminated
-
Tadas CesnaitisUnknownHeart; Surgery, Heart, Functional Disturbance as ResultLithuania
-
Qilu Pharmaceutical Co., Ltd.Recruiting
-
Onorach Clinical LtdCompleted